Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant... by Y. Uehara, Y. Takeyasu, T. Yoshida, A. Tateishi, M. Torasawa, Y. Hosomi, K. Masuda, Y. Shinno, Y. Matsumoto, Y. Okuma, Y. Goto, H. Horinouchi, N. Yamamoto, Y. Ohe

Get full text